April 30, 2025

stat

Investment

We’re reading about FDA approval delay, Merck U.S. investment

Top of the morning to you. And a fine one it is. Lots of sunshine and clear blue skies are once again enveloping the Pharmalot campus, where the official mascots are bounding about the grounds in search of creatures to terrorize. As for us, we are as busy as ever hunting and gathering items of

Read More
Investors

FDA’s ‘key man’ Peter Marks is out. Biotech investors will now deal with the consequences

Robert F. Kennedy Jr. forcing Peter Marks out of the Food and Drug Administration has blown a hole in the agency’s leadership ranks and threatens to unmoor the oversight of drugs and vaccines from bedrock scientific principles.  For biotech investors, Marks’ ouster is a worst-case scenario realized — an FDA riven by dysfunction and uncertainty.

Read More
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept All”, you consent to the use of ALL the cookies. However, you may visit "Cookie Settings" to provide a controlled consent. View more
Accept
Decline